Peginterferon alfa-2a Injection
Brand names: Pegasys
Category: Antiviral
FDA status: Resolved · Last FDA update: Aug 27, 2026 · First posted: Jan 24, 2025 · 1 manufacturers, 2 listed presentations
As of Aug 27, 2026, the FDA lists Peginterferon alfa-2a Injection as shortage resolved. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4) NDC 82154-0451-4 |
pharmaand GmbH (pharma&) | Not specified | - |
| Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1) NDC 82154-0449-1 |
pharmaand GmbH (pharma&) | Not specified | - |
Related medications in shortage
Other Antiviral medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Peginterferon alfa-2a Injection (FDA data as of Aug 27, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Peginterferon alfa-2a Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/peginterferon-alfa-2a-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).